ab108656 is intended for the quantitative determination of the cancer antigen Prostate Specific Antigen (f-PSA) concentration in Human serum.
Human Prostate Specific Antigen is a 33 kD serineproteinase which, in Human serum, is predominantly bound to alpha 1-antichymotrypsin (PSA-ACT) and alpha 2-macroglobulin (PSA-AMG). Trace amounts of alpha 1-antitrypsin and inter-alpha trypsin inhibitor bound to PSA can also be found. Any remaining PSA is in the free form (f-PSA). Current methods of screening men for prostate cancer utilize the detection of the major PSA-ACT form. Levels of 4.0 ng/ml or higher are strong indicators of the possibility of prostatic cancer. However, elevated serum PSA levels have also been attributed to benign prostatic hyperplasia and prostatitis, leading to a large percentage of false positive screening results. A potential solution to this problem involves the determination of free PSA levels. Preliminary studies have suggested that the percentage of free PSA is lower in patients with prostate cancer than those with benign prostatic hyperplasia. Thus, the measurement of free serum PSA in conjunction with total PSA, can improve specificity of prostate cancer screening in selected men with elevated total serum PSA levels, which would subsequently reduce unnecessary prostate biopsies with minimal effects on cancer detection rates.
|Components||1 x 96 tests|
|Enzyme Conjugate Reagent||1 x 22ml|
|Mouse monoclonal anti-Free PSA-coated microtiter plate||1 unit|
|PSA reference standard set||6 vials|
|Stop Solution||1 x 11ml|
|TMB Substrate Solution||1 x 11ml|
|Zero Buffer||1 x 13ml|
Our Abpromise guarantee covers the use of ab108656 in the following tested applications.
|Sandwich ELISA||Use at an assay dependent dilution.|
ab108656 has not yet been referenced specifically in any publications.